|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||83.53 - 83.97|
|52 Week Range||77.04 - 98.52|
|Beta (5Y Monthly)||0.52|
|PE Ratio (TTM)||21.17|
|Forward Dividend & Yield||3.20 (3.83%)|
|Ex-Dividend Date||Mar. 04, 2021|
|1y Target Est||104.80|
The Zacks Analyst Blog Highlights: Facebook, Walmart, Novartis, PayPal and Advanced Micro Devices
Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), Walmart Inc. (WMT), and Novartis AG (NVS).
ZURICH (Reuters) -Swiss drugmaker Novartis said on Tuesday it has bought gene therapy specialist Arctos Medical for an undisclosed amount, aiming to boost its efforts to find treatments for severe vision loss. Arctos's technology is a potential way to treat inherited retinal dystrophies (IRDs) and other diseases that involve photoreceptor loss, such as age-related macular degeneration (AMD). Existing gene therapy treatments aim to correct a specific gene, so only a small number of patients can benefit, Novartis said.